Dive Brief: Adagio Therapeutics said it will ask the Food and Drug Administration for emergency authorization of its COVID-19 drug after announcing Wednesday that the antibody …
Dive Brief: Adagio Therapeutics CEO Tillman Gerngross has agreed “in principle” to resign as head of the COVID-19 drug developer amid confusion over whether its …
The findings are a huge disappointment for Adagio, which billed ADG20 as a weapon that could neutralize a wide range of variants and help with …
